SCOPUS 정보 검색 플랫폼

Journal of Drugs in Dermatology

Volumn 7, Issue 9, 2008, Pages 891-893

Cutaneous drug eruptions induced by sorafenib: A case series

(4) Maddox, Jessica S a Kung, Elaine F a Petronic Rosic, Vesna a Sethi, Aisha a

a UNIVERSITY OF CHICAGO (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; SORAFENIB;

ADULT; AGED; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG ERUPTION; ERYTHEMA; FEMALE; HUMAN; MIDDLE AGED; NEOPLASM; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; DRUG ERUPTIONS; ERYTHEMA; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 58249084757 PISSN: 15459616 EISSN: None Source Type: Journal
DOI: None Document Type: Article

Times cited : (8)

References (7)

1
- 33646204716
- Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors
- Richly H, Henning BF, Kupsch P, et al. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol. 2006;17:866-873.
- (2006) Ann Oncol , vol.17 , pp. 866-873
- Richly, H.¹ Henning, B.F.² Kupsch, P.³

2
- 33748325763
- Sorafenib in advanced melanoma: A Phase II randomised discontinuation trial analysis
- DOI 10.1038/sj.bjc.6603291, PII 6603291
- Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a phase II randomized discontinuation trial analysis. B J Cancer. 2006;95:581-586. (Pubitemid 44325897)
- (2006) British Journal of Cancer , vol.95 , Issue.5 , pp. 581-586
- Eisen, T.¹ Ahmad, T.² Flaherty, K.T.³ Gore, M.⁴ Kaye, S.⁵ Marais, R.⁶ Gibbens, I.⁷ Hackett, S.⁸ James, M.⁹ Schuchter, L.M.¹⁰ Nathanson, K.L.¹¹ Xia, C.¹² Simantov, R.¹³ Schwartz, B.¹⁴ Poulin-Costello, M.¹⁵ O'Dwyer, P.J.¹⁶ Ratain, M.J.¹⁷

3
- 33744984843
- Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
- Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;16:2505-2511.
- (2006) J Clin Oncol , vol.16 , pp. 2505-2511
- Ratain, M.J.¹ Eisen, T.² Stadler, W.M.³

4
- 33749849376
- Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor
- DOI 10.1111/j.1365-2230.2006.02223.x
- Lacoutour ME, Sesai A, Soltani K, et al. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exper Dermatol. 2006;31:783-785. (Pubitemid 44563396)
- (2006) Clinical and Experimental Dermatology , vol.31 , Issue.6 , pp. 783-785
- Lacouture, M.E.¹ Desai, A.² Soltani, K.³ Petronic-Rosic, V.⁴ Laumann, A.E.⁵ Ratain, M.J.⁶ Stadler, W.M.⁷

5
- 0033762498
- The EGF receptor- an essential regulator of multiple epidermal functions
- Jost M, Kari C, Rodeck U. The EGF receptor- an essential regulator of multiple epidermal functions. Eur J Dermatol. 2000;10:505-510.
- (2000) Eur J Dermatol , vol.10 , pp. 505-510
- Jost, M.¹ Kari, C.² Rodeck, U.³

6
- 80052907826
- Available at: Accesssed July 1, 2007
- Rx List. Nexavar: Pharmokinetics. Available at: http://www.rxlist.com/ cgi/generic/nexavar-cp.htm. Accesssed July 1, 2007.
- Nexavar: Pharmokinetics

7
- 21344462378
- Cutaneous side-effects of kinase inhibitors and blocking antibodies
- Robert C, Sorio JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet. 2005;6:491-499.
- (2005) Lancet , vol.6 , pp. 491-499
- Robert, C.¹ Sorio, J.C.² Spatz, A.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.